Topical application of the serotonin2 agonist, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane or DOI, in a dose of 30 jig/side to the intermediate area of the ventrolateral surface of the medulla produced a significant increase in mean arterial pressure with no significant change in heart rate both in intact animals (n=8) and in cervically vagotomized animals (n=3). The pressor response of DOI was blocked by pretreatment of the intermediate area with ketanserin, a serotonin2 antagonist (n =7). Pretreatment with intravenous phentolamine did not block the pressor response of DOI (n=3). However, this pressor response could be counteracted by intravenous propranolol (n=5) or by bilateral stellate ganglionectomy (n=3). These data suggest that sympathoexcitation by centrally applied DOI selectively increased cardiac inotropy but not chronotropy. Further studies indicate that DOI increased contractile force without increasing heart rate and that the positive inotropic effect of DOI could be counteracted by bilateral stellate ganglionectomy. Bilateral microinjections of DOI into the subretrofacial nucleus in a dose of 100 ng (n=3) and a dose of 300 ng (n=3) increased mean arterial blood pressure by 23±2 and 44±6 mm Hg, respectively, without producing any changes in heart rate. These data suggest that DOI has a central site of action in the ventrolateral medulla, presumably at the subretrofacial nucleus, which leads to selective sympathoexcitation of the cardiac ventricles. (Circulation Research 1990;67:1267-1280 W e recently reported evidence that suggested that serotonin (5 -HT) applied topically to the intermediate area of the ventrolateral medulla of the cat could stimulate serotonin2 (5-HT2) receptors, resulting in a rise in arterial blood pressure.' Indeed, our evidence for making such a statement was very indirect and consisted of demonstrating that blockade of 5-HT2 receptors at the intermediate area with topical application of the 5 -HT2 receptor antagonist drug ketanserin, at the same site, augmented the hypotensive effect of 5 -HT. Presumably, the hypotensive effect of 5 -HT was a result of activation of 5 -HT1A From the Departments of Pharmacology (area of the ventrolateral surface of the medulla would cause an increase in blood pressure. We chose to look at this area initially because it has been shown that many drugs that have a central action on cardiovascular activity and sympathetic outflow often act at the intermediate area.5,6 To this end, we evaluated the effects of topical application to the intermediate area of the selective 5-HT2 agonist agent 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, commonly referred to as DOI. This compound has been shown to selectively label 5-HT2 receptor binding sites and has been proposed as a selective 5-HT2 receptor agonist.7-9 Respiratory activity also was monitored because neurons
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In testing the statement that activation of central nervous system 5-HT2 receptors causes an increase in sympathetic outflow, resulting in an increase in blood pressure, we first sought to determine whether activation of 5 -HT2 receptors at the level of the intermediate area of the ventrolateral surface of the medulla would cause an increase in blood pressure. We chose to look at this area initially because it has been shown that many drugs that have a central action on cardiovascular activity and sympathetic outflow often act at the intermediate area.5,6 To this end, we evaluated the effects of topical application to the intermediate area of the selective 5-HT2 agonist agent 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, commonly referred to as DOI. This compound has been shown to selectively label 5-HT2 receptor binding sites and has been proposed as a selective 5-HT2 receptor agonist.7-9 Respiratory activity also was monitored because neurons 1268 Circulation Research Vol 67, No 5, November 1990 reached by diffusion of drugs topically applied to the intermediate area not only affect cardiovascular function but also affect breathing.6
Materials and Methods General
Experiments were performed on adult cats of either sex, weighing between 1.7 and 4.3 kg. Anesthesia was induced and maintained with a single intravenous dose of a-chloralose (75 mg/kg). Rectal temperature was monitored and maintained between 37 .00 and 38.00C with an infrared heating lamp connected to a thermistor. The femoral artery and vein were cannulated for the measurement of arterial blood pressure and for the systemic administration of drugs, respectively. Lead II of the electrocardiogram was monitored, and heart rate was determined by measurement of the RR interval. The trachea was cannulated and fitted with a Fleisch No. 0 pneumotachograph connected to a respiratory flow transducer (HP 4730A, Hewlett-Packard Co., Waltham, Mass.). The airflow signal obtained from the transducer was integrated with a Hewlett-Packard respiratory integrator (HP 8815A) to obtain tidal volume. Respiratory rate was obtained from fast tracings of the flow signal, and respiratory minute volume was calculated as the product of tidal volume and respiratory rate. All respiratory and cardiovascular parameters were recorded simultaneously on a Hewlett-Packard eight-channel recorder (HP 7758B).
Control measurements were taken at approximately 5-minute intervals for at least 30 minutes before the administration of drugs in each experiment. Once a drug was administered, measurements were made at the time at which peak responses occurred and then at 5-minute intervals thereafter until cardiorespiratory activity had returned to the predrug level or had stabilized at a new level.
Ventral Surface Application of Drugs
To apply drugs on the intermediate area of the ventrolateral surface of the medulla, the following procedures were performed. After a longitudinal midline incision was made in the neck, the trachea and esophagus were transected and retracted cephalad. The prevertebral muscles were bluntly dissected away from the base of the skull, which then was removed. The dura and arachnoid membranes then were removed. Cottonoid wicks were placed on all edges of the craniotomy to prevent excessive pooling of cerebrospinal fluid during the experiment and, thereby, prevented excessive dilution and spread of the drug solutions.
Drugs were applied to the intermediate area of the ventral surface of the medulla with 2-mm-diameter pledgets of No. 2 filter paper that were soaked with 2 ,ul of drug solutions. Additional details of the procedure and location of drug application have been described previously.10 Administration of 2 ,ul of drug or control solutions resulted in saturation of the pledgets. In each experiment, control solutions of 2 ,ul of the solvents used to dissolve DOI, ketanserin, N-methyl-D-aspartic acid (NMDA), and prazosin were examined. Pledgets soaked in the solvents used to dissolve these drugs did not produce significant changes in cardiorespiratory activity.
Stellectomy
Animals were ventilated artificially with room air.
Crescent-shaped incisions were made bilaterally ipto the chest wall from the manubrium to the posterior tip of the scapula. The various muscle layers were excised, revealing the rib cage. On each side, the second rib was isolated from the intercostal muscles and excised. Both stellate ganglia were then dissected away from the surrounding fascia and removed. To determine the effectiveness of bilateral stellectomy in abolishing sympathetic neural effects on the heart, the degree of reflex-induced sinus tachycardia produced by sodium nitroprusside infused intravenously at a rate of 200 ,g/mVmin for 15 seconds was observed before and after extirpation of the stellate ganglia. With both stellate ganglia intact, sodium nitroprusside infusion lowered mean blood pressure -31±5 mm Hg and raised heart rate +39±7 beats/min. After bilateral stellate ganglionectomy, sodium nitroprusside infusion lowered mean arterial pressure -36+ 10 mm Hg without appreciably changing heart rate (-2±+1 beats/min). Hence, the lack of reflex-induced sinus tachycardia with sodium nitroprusside indicated successful stellate ganglionectomy.
Experiments of Contractile Force
In some animals, the effects of drugs applied to the intermediate area on contractile force of the right ventricle were examined in the absence and presence of bilateral stellate ganglionectomy. These animals were ventilated artificially with room air. A calibrated strain gauge arch (Warren Research Products, Charleston, S.C.) was sewn onto the right ventricle and stretched by 50% of its initial length. Right ventricular force was measured because changes in systemic pressures have relatively less effect on right than on left ventricular diastolic fiber length.11,12 The leads of the arch were connected to a preamplifier (model 7P1A, Grass Instrument Co., Quincy, Mass.), which was coupled to a dynograph recorder (model R611, Sensormedic, Anaheim, Calif.). A bipolar electrode was sutured onto the right atrial appendage. The electrode served as a pacing electrode and was connected to a stimulator (Grass Instruments). Blood pressure and lead II of the electrocardiogram were monitored on a recorder (model 220, Gould Instruments, Cleveland).
Microinjection Technique
The ventral surface of the medulla was exposed in the same manner described above. the tips were cut to approximately 15 ,um i.d. The pipette was then mounted on a David Kopf electrode manipulator. Each barrel of the pipette was connected to polyethylene tubing and filled using negative pressure. One barrel was filled with a 100 mM solution of L-glUtamic acid, while the other was filled with DOI, which also contained a 1% solution of fast green (Sigma Chemical Co., St. Louis) for subsequent histological verification of the injection site. Two microinjection sites were selected in evaluating the site of action of DOI. One of these sites was the locus where microinjections of L-glutamic acid produce an increase in blood pressure, namely, the nucleus reticularis rostroventrolateralis. 13 In that study, a volume of 200 nl made up the microinjectate. Since then, our laboratory has observed effects with volumes of microinjectate as low as 10 nl. With this reduced volume, we have been able to localize better this "L-glutamic acid-sensitive site." This site also has been described by McAllen14 as the subretrofacial nucleus (SRFn). The coordinates used for microinjection into the SRFn were 6.0-7.0 mm caudal to the foramen cecum, 4.0 mm lateral to the midline, and 1.0-1.5 mm below the ventral surface. With these coordinates, a micropipette was placed on each side. Then, using a series of pressure injections (30 psi, 400-1,000 msec in duration) with a pneumatic pump (model PV 800, World Precision Instruments, New Haven, Conn.), 100 mM L-glutamic acid in a volume of 20-60 nl was microinjected on both sides. If both microinjections produced a pressor response, then it was assumed that both micropipettes were in the SRFn. When the blood pressure returned to baseline values, DOI in a volume of 20-40 nl was microinjected bilaterally.
The other site selected within the ventrolateral medulla has been described as containing a high density of serotonergic cell bodies and has been termed the lateral wings of the B1/B3 cell groups or the parapyramidal region.15,16 Many of the axons of these serotonergic cell bodies terminate in the intermediolateral cell column of the spinal cord, the major site of preganglionic sympathetic neurons. Pharmacological excitation of the parapyramidal cell bodies results in a pressor response. [17] [18] [19] As defined by Marson and Loewy20 for cats, this cluster of serotonergic neurons is just medial and superficial to the SRFn. The coordinates used for the parapyramidal region were 5.0-7.0 mm caudal to the foramen cecum, 3.5 mm lateral to the midline, and 0.3-0.8 mm below the ventral surface. Again, a volume of 20-60 nl of drug solution was microinjected using a series of pressure injections.
After completion of the experiment, the brain stem was removed and fixed in 10% formalin for at least 48 hours. The tissue was then blocked and transferred to a solution of 20% sucrose in phosphate buffered saline for at least 24 hours before sectioning. Fiftymicrometer sections were counterstained with neutral red to facilitate identification of nuclear groups, and the site of microinjection was easily identified by a bright green area; in some cases, tissue damage also marked the micropipette track.
Drugs Used and Drug Preparation
a-Chloralose was obtained from ICN Biomedical, Cleveland, and dissolved in 30 ml heated 0.9% saline. DOI was obtained from Research Biochemicals, Inc., Natick, Mass., and was dissolved in 0.9% saline. Ketanserin tartrate was obtained from Research Biochemicals and was dissolved in distilled water. N-Methyl-Daspartic acid was obtained from Sigma Chemical Co., St. Louis, and was dissolved in 0.9% saline. Prazosin was obtained from Sigma and was dissolved in ethanol and dimethyl sulfoxide and diluted with distilled water. Phentolamine (Regitine) was obtained from CIBA Pharmaceutical Co., Edison, N.J., and was dissolved in 0.9% saline. Propranolol was obtained from Ayerst Laboratories, New York, and was dissolved in 0.9% saline. Sodium nitroprusside was obtained from Elkins-Sinn, Inc., Cherry Hill, N.J., and was reconstituted and diluted in 5% dextrose.
Statistical Analysis
Data were analyzed using the two-tailed paired t test, the two-tailed grouped t test, or one-way analysis of variance with Duncan's multiple range test. The criterion for significance was p<0.05.
Results

Cardiorespiratory Effects of DOI Topically Applied to the Ventral Surface of the Medulla
Eight experiments were performed wherein DOI was applied bilaterally to the ventral surface of the medulla, specifically to the intermediate area where we previously obtained evidence that serotonin could cause a rise in arterial pressure.' Preliminary experiments indicated that a dose of 30 jg/side DOI would produce a consistent response; hence, this dose was used in all the experiments. From the dose-response data obtained by King and Holtman,21
it appears that the 30 gg/side dose falls at a point about 85% of the maximal response. The data obtained are shown in Table 1 . As can be noted, DOI application produced an increase in arterial pressure. This pressor response was not accompanied by any change in heart rate. Respiratory effects also were observed and consisted of decreases in respiratory rate and respiratory minute volume and an increase in tidal volume.
A representative experiment depicting the cardiorespiratory effects of DOI appears in Figure 1 . As can be noted, bilateral application of DOI produced an immediate pressor effect that became maximal within 3 minutes after application. The duration of the response ranged from 10 to 15 minutes. The time action curve for the DOI-induced slowing in respiratory rate was similar to that for the pressor response.
We also tested repeated application of DOI by using the 30 ,ug/side dose on the intermediate area.
In three animals, the initial dose of DOI increased mean arterial pressure 31+5 mm Hg (p<0.05) and decreased respiratory rate by 4±0 breaths/min (p<0.05) without having any noticeable effects on either heart rate (+6+3 beats/min) or tidal volume (+5±4 ml). After the arterial pressure and respiratory rate returned to baseline or stabilized at a new baseline, it was noted that a subsequent application of DOI had no appreciable effect on blood pressure (+ 1+3 mm Hg) and respiratory rate (0+0 breaths/ min). These data suggest that the 5-HT2 receptor rapidly desensitizes after initial exposure to DOI. We also performed studies in which DOI in a dose of 30 ,ug/side was applied to other sites on the ventrolateral medulla where other agents have been shown to exert effects on cardiorespiratory activity. These sites were the rostral area where cholinomimetic agents and opioids alter cardiorespiratory function22,23 and the caudal area where cholinomimetic agents alter 30 ,., ' cardiorespiratory function. 22 The precise location of these sites has been demonstrated in work performed by Gillis and colleagues.10 In the two animals in which DOI was applied to the rostral area, changes in mean arterial blood pressure and heart rate were -8±2 mm Hg and +4±3 beats/min, respectively. Application of DOI to the rostral area also had no noticeable effect on tidal volume (+ 1 ± 1 ml) or respiratory rate (-2±1 breaths/min). In the two animals in which DOI was applied to the caudal area, changes in mean blood pressure and heart rate were +7±2 mm Hg and +3±2 beats/min, respectively. Again, as with the rostral area, application of DOI to the caudal area had no noticeable effects on tidal volume (-1 ± 1 ml) or respiratory rate (-1±0 breaths/min). Table 1 , pretreatment with ketanserin significantly counteracted both the pressor effect and the respiratory changes normally seen with DOI application. A representative experiment illustrating the ability of ketanserin pretreatment to counteract the cardiorespiratory effects of DOI appears in Figure 2 .
Effect of Ketanserin Pretreatment on the
To ensure that ketanserin was exerting its antagonistic effect to DOI by blocking 5 -HT2 receptors and not by exerting a nonselective effect at the intermediate area, we evaluated the effect of ketanserin on the pressor responses elicited by a drug that does not activate 5 -HT2 receptors but activates glutamate receptors. This drug is NMDA, and the data obtained are shown in Table 2 . The dose of NMDA chosen was a dose that elicited a pressor response similar in magnitude to that observed with 30 ,ug/side DOI, namely, 11 ,ug/side NMDA. Application of this dose of NMDA produced a consistent rise in blood pressure without evoking significant changes in respiratory activity. Interestingly, NMDA also produced a significant increase in heart rate along with the increase in arterial blood pressure. Most important, pretreatment with a dose of ketanserin (25 jig/side) that significantly antagonized the cardiorespiratory effects of DOI had no significant blocking effect against NMDA-induced increases in arterial pressure.
During our studies of ketanserin, we confirmed our earlier findings that topical application of this agent per se results in a significant decrease in arterial pressure.' These results are shown in Table 3 , and a representative experiment demonstrating the hypotensive effect of ketanserin appears on the left side of Figure 2 . The data in Table 3 are a summary of all of the experiments obtained with ketanserin and comprise results from experiments in which ketanserin was applied topically to the intermediate area before DOI and NMDA were studied, as well as two experiments in which ketanserin was applied for the purpose of determining whether the effects of intravenous DOI could be altered (see below). As can be noted, ketanserin administration resulted in an average decrease in mean arterial blood pressure of 20 mm Hg. This fall in blood pressure also was associ- We were intrigued by the difference between the effects of ventral surface application of DOI and NMDA on sinus rate. DOI elicited a pressor effect that was not accompanied by an increase in heart rate (Table 1) ; on the other hand, NMDA elicited a pressor effect of similar magnitude as DOI that was accompanied by an increase in sinus rate ( Table 2 ). The absence of a sinus rate increase could have been due to DOI-induced activation of the vagus either directly by diffusion from the ventral surface to the nucleus ambiguus or indirectly because of pressor-induced baroceptor activation. Vagal activation thus could have canceled out the sympathetic effects on the atria, thereby explaining the lack of a heart rate increase with DOI. To determine whether DOI-induced vagal activation was responsible for the lack of a sinus rate increase, bilateral cervical vagotomy was performed in three animals before topical application of DOI to the intermediate area. Data obtained are shown in Table 4 and indicate that the pressor effect of DOI still is not accompanied by an increase in sinus rate, although vagotomy appeared to attenuate the effect of DOI on respiratory rate (Table 4 ).
In the next set of experiments, we focused on whether the DOI-induced pressor response was the primary result of 1) an increase in sympathetic outflow to the vasculature, 2) an increase in sympathetic outflow to the heart, or 3) increases of sympathetic outflow to both the vasculature and the heart. Because sinus rate was unaffected by DOI in vagotomized animals, we first focused on whether DOI was selectively increasing sympathetic outflow to the vasculature. For this purpose, animals were pretreated with the a1-adrenoceptor antagonist drug phentolamine in a dose known to fully block both a1-and a2-adrenoceptors in cats. 27 As shown in Table 4 , data indicate that prevention of sympathomimetic effects on blood vessels did not reduce significantly the pressor effect of bilateral application of DOI to the intermediate area. Pretreatment Table 1 ). with phentolamine also did not counteract the respiratory effects of DOI.
Next, we pretreated a group of animals with propranolol for the purpose of preventing sympathomimetic effects on the heart. The data obtained are tabulated in Table 4 and indicate that prevention of sympathomimetic effects on the heart by blocking both ,Iland 32-adrenoceptors significantly reduces the pressor effect of DOI. Pretreatment with propranolol, however, did not counteract the respiratory depressant effect of DOI. A representative experiment illustrating the effect of propranolol pretreatment on the pressor response elicited by DOI appears in Figure 3 . In view of the finding that pharmacological denervation of the sympathetic division of the autonomic nervous system to the heart counteracts the DOI-induced pressor responses, we subsequently set out to confirm this finding by using surgical denervation. Such denervation was accomplished by acutely extirpating both stellate ganglia before applying DOI to the intermediate area. Data obtained are shown in Table 4 and indicate that surgical ablation of the sympathetic division of the autonomic nervous system to the heart, like pharmacological ablation of the sympathetic division of the autonomic nervous system to the heart, counteracts the pressor effect of DOI. 
Effect of Topical Application of DOI to the Intermediate Area on Cardiac Contractile Force
The data obtained with propranolol pretreatment and bilateral stellate ganglionectomy on DOI-induced increases in mean blood pressure combined with the lack of sinus rate increases with DOI suggest that DOI, when applied topically to the intermediate area, is raising pressure primarily by increasing cardiac contractile force. The purpose of our next set of experiments, therefore, was to determine whether topical application of DOI to the intermediate area also would increase myocardial contractility. Four experiments were performed in which atrial pacing was not used to control heart rate during contractile force measurements because our data indicate that DOI does not alter heart rate (Table 1 ). As summarized in Figure 4 , there was an increase in contractile force after topical application of DOI to the intermediate area. The time course of action was similar to that observed for blood pressure and respiratory effects already described above. As expected, in this group of animals, mean blood pressure significantly increased (+47+10 mm Hg) while there was no significant change in heart rate (+5+4 beats/min). In three animals that had undergone bilateral stellate ganglionectomy, the effect of DOI on contractile force was evaluated. As shown in Figure 4 , removal of both stellate ganglia significantly counteracted the increase in contractile force. In addition, stellate ganglionectomy significantly attenuated the pressor response. (The pressor effect was +21±2 mm Hg in stellectomized animals compared with a pressor effect of +47+10 mm Hg in the control group,p<0.05 by the t test for grouped data). Again, DOI in stellectomized animals did not produce a significant change in heart rate (-2±4 beats/min).
To further differentiate the mechanism of action of DOI and NMDA, contractile force experiments also were made after topical application of NMDA to the intermediate area of the ventral surface of the medulla. Because NMDA increases both arterial pressure and heart rate ( Table 2) , we were interested to see whether this excitatory amino acid also would increase contractile force. Because NMDA previously had been observed to change heart rate, atrial pacing was instituted to ensure that the heart rate remained constant during the time of NMDA application. The pacing rate was set at 15-20 beats/min faster than the intrinsic sinus rate of each animal and averaged 245 18 beats/min. Four experiments were performed, and the data are summarized in Figure 4 .
As can be seen, in intact animals, NMDA (11 ,ug/ side) produced an increase in contractile force to a degree similar to that seen with DOI. This increase in contractile force was accompanied by increases in arterial pressure (+48+± 3 mm Hg). Interestingly, however, bilateral stellate ganglionectomy did not significantly counteract NMDA-induced increases in contractile force (Figure 4) . Similarly, the pressor effect of NMDA was not altered by stellate ganglionectomy (+39+7 mm Hg in stellectomized animals compared with +48+3 mm Hg in control animals).
Effect of Ketanserin Pretreatment and Propranolol Pretreatment on the Cardiorespiratory Effects of DOI Administered by the Intravenous Route
The purpose of this set of experiments was to determine whether DOI given by the intravenous route raises blood pressure because of an effect in the ventrolateral medulla. DOI was administered as an intravenous bolus injection of 100 ,g/kg to three animals, and the effects on cardiorespiratory function (Table 5 ). Indeed, the pressor effect of intravenous DOI appeared to be somewhat greater than the pressor response observed in control animals not receiving ketanserin ( Table 6) . Because intravenous propranolol also was found to counteract the pressor effect of DOI applied to the intermediate area (Table 5) , experiments were performed to determine whether intravenous propranolol would counteract the pressor effect of intravenously administered DOI. Data obtained from three animals are shown in Table 5 and indicate that propranolol pretreatnent does not counteract the pressor effect produced by a bolus intravenous injection of DOI.
Microinjections of DOI Into the Subretrofacial Nucleus
In an attempt to better localize the site of the pressor effect of DOI within the ventrolateral medulla, this agent was microinjected into a major nucleus that influences central sympathetic outflow and that can be reached by diffusion of drug initially placed on the intermediate area of the ventrolateral medulla. This nucleus is the SRFn.14 Coordinates have been established for locating this nucleus (see "Materials and Methods"). Along with these coordinates, an additional guide for locating the SRFn is to find the site where L-glutamic acid microinjection produces a rapid and marked increase in arterial blood pressure. Hence, these experiments were conducted first by microinjecting 20-60 nl of a 100 mM solution of L-glutamic acid as a test agent for locating the SRFn on each side. After the blood pressure and heart rate had returned to baseline values, the effects of bilateral microinjections of DOI were then determined. A representative experiment illustrating this sequence of microinjections is shown in Figure 5 . As can be seen, microinjection of L-glutamic acid on each side evoked an immediate increase in blood pressure, which was brief in duration. When arterial blood pressure had stabilized, DOI was microinjected bilaterally into the same site in a dose of 1 gg/site. Immediately after microinjection of DOI, there was a striking increase in arterial pressure: mean blood pressure increased from 78 to 112 mm Hg, producing an increase of 34 mm Hg. The location of the micropipette tips in this experiment is illustrated in Figure 6 . As can be seen, the injection sites were within the SRFn.
In subsequent experiments, lower doses of DOI were microinjected into the SRFn of cats that had undergone cervical vagotomy. The doses were 100 and 300 ng/site, and the data obtained are shown in Table 6 . These two doses of DOI appeared to produce a dose-related increase in mean arterial pressure. The response observed with the 300 ng/site microinjection was similar in magnitude to that observed after topical application of 30 jig/side DOI to the intermediate area (compare data in Table 6 with data in Table 1 ). The increases in mean arterial pressure produced by microinjection of 100 and 300 ng/site were not associated with significant changes in heart rate (Table 6 ). The sites of DOI microinjections are shown in Figure 7 : the sites where 100 ng/20 nl DOI had an effect are depicted as closed circles, the sites where 300 ng/20 nl DOI had an effect are depicted as stars, and the sites where 300 ng/20 nl DOI had no effect are depicted as open circles. As shown, 300 ng/site DOI had no effect at regions lateral and rostral to the SRFn. Moreover, 300 ng/site DOI also had no effect when microinjected into an area just lateral to the pyramids and just medial and superficial to the SRFn, an area coincident with the parapyramidal region.
To determine whether the doses of DOT tested by microinjection had exerted their effect because of diffusion of drug to sites other than the SRFn (which could be reached after diffusion following topical application to the intermediate area), experiments were performed wherein DOI in doses found to exert pressor effects after microinjection into the SRFn were Table 6 and indicate that topical application of 100, 300, and 1,000 ng/side (i.e., 1 ,ug/side) had no significant effect on mean arterial blood pressure.
Discussion
The major new findings from our study are as follows: 1) stimulation of 5-HT2 receptors in the ventrolateral medulla, presumably in the SRFn, increases sympathetic outflow, resulting in an increase in arterial blood pressure; and 2) activation of 5 -HT2 receptors in the ventrolateral medulla results in a nonuniform increase in sympathetic outflow. The outflow appears to be increased primarily to ventricular muscle with either no or relatively minor changes in outflow to the sinus node and vascular beds.
Evidence that activation of 5-HT2 receptors in the ventrolateral medulla increases sympathetic outflow, resulting in an increase in arterial blood pressure, was obtained initially in our previous studies with 5 -HT applied to the intermediate area of the ventral surface of the medulla.1 In that study, topical application of 5-HT to the intermediate area produced a small but statistically significant hypotensive effect. By blocking 5 -HT2 receptors at this site, hypotension resulting from topical application of 5-HT was enhanced significantly. These data implied that 5-HT was activating 5-HT2 receptors in the intermediate area, resulting in an increase in arterial blood pressure. With the introduction of a specifically acting agonist for the 5 -HT2 receptor, namely DOI, we were able to test directly whether activation of this receptor subtype would result in an increase in arterial blood pressure. Indeed, topical application of DOI to the intermediate area did produce a consistent rise in arterial blood pressure. Similar results of DOI in anesthetized cats recently have been reported by King and Holtman.21 Evidence that the effect of DOI was mediated through activation of 5 -HT2 receptors was obtained using the 5-HT2 receptor antagonist drug ketanserin. 28 Topical application of ketanserin to the intermediate area prevented the pressor effects of subsequent administration of DOI to the same site. The selectivity of ketanserin for blocking the 5-HT2 receptor was demonstrated by showing that a dose of ketanserin that blocked the pressor effect of DOI did not block the pressor effect of NMDA applied topically to the intermediate area. Because ketanserin also blocks a1adrenoceptors,24-26,28 it was important to show that the interaction between ketanserin and DOI was not due to the a1-adrenoceptor blocking property of ketanserin.
To this end, it was noted that the prototypic a1adrenoceptor antagonist, prazosin, did not antagonize the DOI-induced pressor response.
The lack of a pressor effect of DOI topically applied to either the rostral area or the caudal area of the ventral surface of the medulla indicated that DOI was exerting its effect at a nucleus associated with the intermediate area. The major nucleus associated with the intermediate area and shown to influence sympathetic outflow in the cat is the SRFn.14 Hence, experiments were performed to determine whether the pressor effect of topically applied DOI was due to diffusion to this nucleus. This was tested by microinjection of DOI bilaterally into the SRFn in doses that were inactive after topical application to the intermediate area and then observing the same spectrum of cardiovascular effects that were obtained after topical application of DOI to the intermediate area in a dose of 30 ,ug/side. In contrast, bilateral microinjections of 300 ng/site DOI into the parapyramidal region had no effect on blood pressure. As mentioned earlier, the parapyramidal region also has been shown to influence sympathetic outflow. [17] [18] [19] Our data strongly indicate that the site of action of DOI to increase sympathetic outflow and raise arterial blood pressure is the subretrofacial nucleus, not the parapyramidal region.
Evidence that activation of 5-HT2 receptors in the ventrolateral medulla results in a nonuniform increase in sympathetic outflow is based on several findings, and they are as follows. 1) Both topical application of DOI to the intermediate area and microinjection of DOI into the subretrofacial nucleus in vagotomized animals cause an increase in arterial blood pressure without any significant change in heart rate, indicating that DOI increases sympathetic outflow but not to the sinus node. 2) The pressor effect of DOI applied to the intermediate area is counteracted either by systemic propranolol pretreatment or by bilateral stellate ganglionectomy but not by systemic phentolamine pretreatment. These observations indicate that DOI increases sympathetic outflow to the heart (with the exception of the sinoatrial node) but not to the vasculature. 3) The pressor effect of topically applied DOI is associated with an increase in cardiac contractile force, and bilateral stellate ganglionectomy counteracts both DOI-induced increases in cardiac contractile force and in arterial blood pressure. This latter result provides confirmatory evidence that DOI is selectively increasing sympathetic outflow to the heart (with the exception of the sinoatrial node). 4) In contrast to the pressor effect of DOI, the pressor effect of NMDA topically applied to the intermediate area is associated with both an increase in heart rate and an increase in cardiac contractile force that is not counteracted by bilateral stellate ganglionectomy. This latter finding in addition to the earlier findings of McAllen29 indicates that activation of neurons in the ventrolateral medulla (intermediate area) causes widespread increases in sympathetic outflow, whereas activation of 5-HT2 at the same site causes a selective increase in sympathetic outflow to the heart (i.e., to the ventricles). Based on these findings, we postulate that one reason neurons in the central nervous system can be selectively engaged to perform a physiological function is because of the pattern of distribution of neurotransmitter receptors on neu-rons, such as the 5-HT2 receptor on certain neurons within the SRFn.
Other investigators have obtained data indicating that systemic administration of DOI can increase central sympathetic outflow3,4'30 and arterial blood pressure.3,4,29-32 Heart rate was increased slightly in the initial study by McCall and colleagues,3 but not in the later study4 in which a similar dose range of DOI was used. Other investigators have reported that DOI, in doses that exert a pressor effect, does not increase the heart rate. [30] [31] [32] Most important, McCall and colleagues3 reported that DOI increases sympathetic outflow through a central nervous system site of action. Their evidence was based on the finding that DOI given intravenously increases sympathetic discharge in preganglionic splanchnic fibers in baroreceptor-denervated cats. In our study, we observed that intravenously administered DOI increased the arterial pressure. This finding raises the question as to whether intravenously administered drug acts at a site in the ventrolateral medulla to exert a pressor effect. To test this point, we repeated our intravenous studies under conditions for which the pressor effect of topically applied DOI to the ventrolateral medulla was inhibited. These conditions were after topical application of ketanserin to the intermediate area of the ventrolateral medulla and after intravenous administration of propranolol. Under both conditions, intravenously administered DOI produced a striking increase in arterial blood pressure. Based on these findings, we conclude that intravenous DOI is not exerting a pressor effect by stimulating 5 -HT2 receptors in the region of the ventrolateral medulla.
According to Dabire and colleagues,31 DOI produces a greater increase in arterial blood pressure in the pithed rat as compared with the intact rat. This result indicates that the central nervous system is not required for the action of intravenous DOI to raise arterial blood pressure. Indeed, it has been shown that there are 5-HT2 receptors on vascular tissue and that activation of these receptors results in vasoconstriction. [33] [34] [35] The question we have not addressed in our study is whether the DOI-induced increase in central sympathetic outflow after systemic administration is due to an interaction of DOI with 5-HT2 receptors located in the ventrolateral medulla. We suspect that this is the case; however, experiments need to be performed to test this point.
Because activation of 5-HT2 receptors in the ventrolateral medulla results in an increase in central sympathetic outflow, it is important to consider whether blockade of 5-HT2 receptors in the ventrolateral medulla results in a decrease in central sympathetic outflow. In the present study, as in the case of our earlier study,1 we observed a significant decrease in arterial blood pressure after bilateral topical application of ketanserin to the intermediate area. While these data are in agreement with the observations of others indicating that ketanserin has a central hypotensive effect,36-38 it has been assumed that this central hypotensive effect is due to the actions of ketanserin as an a,-adrenoceptor antagonist rather than as a 5-HT2 receptor antagonist.36 '37 In addition, ketanserin has been shown to have relatively high affinity for receptors other than the 5-HT2 receptor and the a1-adrenoceptor,2' and these other receptor effects might contribute to its central hypotensive action. Further studies with newer and more selective 5 -HT2 antagonists, such as LY-53857, 25, 39 and their effects at the ventrolateral medulla need to be performed to resolve this important question.
In our study, we also observed changes in respiratory activity after topical application of DOI to the intermediate area. Specifically, these changes were an increase in tidal volume and a decrease in respiratory rate. This decrease in respiratory rate has been described in the study by King and Holtman.21 Previously, we reported that topical application of drugs that activate 5--HT1A receptors to the intermediate area decreases tidal volume and increases respiratory rate.1'40A4l Therefore, just as activation of 5-HT2 receptors and activation of 5-HT1A receptors in the intermediate area have opposing effects on blood pressure, activation of these two subtypes of serotonergic receptors also has opposing actions on respiratory activity. Furthermore, the respiratory effects of topically applied DOI were lost after microinjection of DOI in the SRFn. Therefore, it appears that the central site of action for the respiratory effects of DOI is not the SRFn but some other area. More studies need to be performed to elucidate the site of DOI's respiratory effects.
In summary, our data indicate that there is a central pathway for selective sympathoexcitation of the heart, leading to an increase in cardiac inotropy without an increase in cardiac chronotropy. The pathway for this selective sympathetic outflow to the cardiac ventricles is mediated by activation of 5-HT2 receptors on neurons located within the ventrolateral medulla, most likely within the SRFn. Although it has been shown that it is possible to selectively increase sympathetic outflow from the SRFn to different vascular beds,'4 to our knowledge, our report is the first that documents selective sympathoexcitation to different areas within a specific organ, namely, the heart.
